title: Failure of anti-TNF therapy to reactivate previously septic prosthetic joints.
abstract: A patient with long-standing rheumatoid arthritis was admitted with Streptococcus pneumoniae septicaemia and bilateral septic knee joints. He was treated conservatively with intravenous antibiotics and arthroscopic washouts and discharged home on oral antibiotics. Six months posthospital discharge, following re-exacerbation of arthritis, an informed consent was given by the patient to continue antitumour necrosis factor therapy. After 5 years of observation, there has been no recurrence of sepsis and the rheumatoid arthritis remains in remission.
authors.affiliation: Rheumatology Department, University of Sydney, Sydney, New South Wales, Australia. nicholas.manolios@sydney.edu.au
authors.forename: Nicholas
authors.initials: N
authors.lastname: Manolios
authors.forename: Anthony
authors.initials: A
authors.lastname: Burneikis
authors.forename: David
authors.initials: D
authors.lastname: Spencer
authors.forename: Graydon
authors.initials: G
authors.lastname: Howe
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007720:Knee Prosthesis / Q000009:adverse effects*; D008297:Male; D011008:Pneumococcal Infections / Q000150:complications* / Q000188:drug therapy*; D016459:Prosthesis-Related Infections / Q000150:complications* / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept